Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis : A Population-based Cohort Study. / Prosberg, Michelle V; Vester-Andersen, Marianne K; Andersson, Mikael; Jess, Tine; Andersen, Jon Thor Trærup; Vind, Ida; Bendtsen, Flemming.

In: Inflammatory Bowel Diseases, Vol. 22, No. 4, 04.2016, p. 925-932.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Prosberg, MV, Vester-Andersen, MK, Andersson, M, Jess, T, Andersen, JTT, Vind, I & Bendtsen, F 2016, 'Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study', Inflammatory Bowel Diseases, vol. 22, no. 4, pp. 925-932. https://doi.org/10.1097/MIB.0000000000000700

APA

Prosberg, M. V., Vester-Andersen, M. K., Andersson, M., Jess, T., Andersen, J. T. T., Vind, I., & Bendtsen, F. (2016). Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study. Inflammatory Bowel Diseases, 22(4), 925-932. https://doi.org/10.1097/MIB.0000000000000700

Vancouver

Prosberg MV, Vester-Andersen MK, Andersson M, Jess T, Andersen JTT, Vind I et al. Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study. Inflammatory Bowel Diseases. 2016 Apr;22(4):925-932. https://doi.org/10.1097/MIB.0000000000000700

Author

Prosberg, Michelle V ; Vester-Andersen, Marianne K ; Andersson, Mikael ; Jess, Tine ; Andersen, Jon Thor Trærup ; Vind, Ida ; Bendtsen, Flemming. / Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis : A Population-based Cohort Study. In: Inflammatory Bowel Diseases. 2016 ; Vol. 22, No. 4. pp. 925-932.

Bibtex

@article{7c00340b596f4279b51f08de13b7fc91,
title = "Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study",
abstract = "BACKGROUND: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis.METHODS: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of ≥80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients.RESULTS: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients.CONCLUSIONS: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.",
keywords = "Administration, Oral, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Cohort Studies, Colitis, Ulcerative, Female, Follow-Up Studies, Humans, Male, Mesalamine, Middle Aged, Patient Compliance, Prognosis, Recurrence, Risk Factors, Self Care, Time Factors",
author = "Prosberg, {Michelle V} and Vester-Andersen, {Marianne K} and Mikael Andersson and Tine Jess and Andersen, {Jon Thor Tr{\ae}rup} and Ida Vind and Flemming Bendtsen",
year = "2016",
month = apr,
doi = "10.1097/MIB.0000000000000700",
language = "English",
volume = "22",
pages = "925--932",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "Lippincott Williams & Wilkins",
number = "4",

}

RIS

TY - JOUR

T1 - Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis

T2 - A Population-based Cohort Study

AU - Prosberg, Michelle V

AU - Vester-Andersen, Marianne K

AU - Andersson, Mikael

AU - Jess, Tine

AU - Andersen, Jon Thor Trærup

AU - Vind, Ida

AU - Bendtsen, Flemming

PY - 2016/4

Y1 - 2016/4

N2 - BACKGROUND: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis.METHODS: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of ≥80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients.RESULTS: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients.CONCLUSIONS: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.

AB - BACKGROUND: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis.METHODS: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of ≥80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients.RESULTS: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients.CONCLUSIONS: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.

KW - Administration, Oral

KW - Adult

KW - Aged

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Cohort Studies

KW - Colitis, Ulcerative

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Mesalamine

KW - Middle Aged

KW - Patient Compliance

KW - Prognosis

KW - Recurrence

KW - Risk Factors

KW - Self Care

KW - Time Factors

U2 - 10.1097/MIB.0000000000000700

DO - 10.1097/MIB.0000000000000700

M3 - Journal article

C2 - 26818426

VL - 22

SP - 925

EP - 932

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -

ID: 171580068